Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | SCD | O00767 | 7/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17640680 | 0.76 | PIK3CD (0.51) | PIK3CDNPC1MAPTRAB9APTGDR | |
| SCHEMBL17640681 | 0.71 | ATM (0.48) | PIK3CD | |
| SCHEMBL7278679 | 0.69 | KMT2A (0.46) | NPC1RAB9A | |
| SCHEMBL19307654 | 0.69 | PIK3CD (0.49) | PIK3CDNPC1MAPTRAB9APTGDR | |
| SCHEMBL11529716 | 0.63 | L3MBTL1 (0.46) | MAPTRAB9A | |
| SCHEMBL5223669 | 0.62 | CLK4 (0.54) | NPC1MAPTRAB9ACLK4 | |
| SCHEMBL17103886 | 0.61 | MMP1 (0.49) | MAPT | |
| SCHEMBL15056387 | 0.61 | MMP1 (0.49) | MAPTRAB9A | |
| SCHEMBL17640675 | 0.61 | PIK3CD (0.49) | PIK3CDNPC1MAPTRAB9APTGDR | |
| SCHEMBL9360061 | 0.61 | MMP1 (0.52) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208066-B2 | Imidazopyridazine compounds and their use | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208066-B2 | Imidazopyridazine compounds and their use | PIK3R5, PIK3CD, INPP5D | PIK3CD 2/4885SCD 4751/4885NPC1 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.